The Texas Medication Algorithm Project (TMAP) is a controversial corporate-sponsored set of psychiatric management guidelines designed to enable doctors to systematically screen and treat patients for diagnosed mental disorders within Texas' publicly-funded mental health care system. TMAP was initiated in the fall of 1997 to provide more uniform early intervention screening and treatment for Texas children.
TMAP arose from a collaboration than began in 1995 between pharmaceutical companies, the University of Texas Southwestern, and the Texas Department of Mental Health and Mental Retardation (TDMHMR). The pharmaceutical companies who funded the development of TMAP include Janssen Pharmaceutica, Johnson & Johnson, Eli Lilly, Astrazeneca, Pfizer, Novartis, Janssen-Ortho-McNeil, GlaxoSmithKline, Abbott, Bristol Myers Squibb, Wyeth-Ayerst and Forrest Laboratories.
TMAP is a decision-tree medical algorithm, the design of which was based on the expert opinions of prescribers. The drugs recommended as "first line treatment", are produced by the sponsors of the guidelines: Risperdal, Zyprexa, Seroquel, Geodone, Depakote, Paxil, Zoloft, Celexa, Wellbutron, Zyban, Remeron, Serzone, Effexor, Buspar, Adderall and Prozac.
See also
External Links
- Mind Freedom News Release: President Bush and the Shrinking of the USA
- SSRICitizen.org: The Texas Medication Algorithm Project
- President's New Freedom Commission on Mental Health
- NewMediaExplorer.org
- Texas Medication Algorithm Project guidelines produce improvements in patients with major depressive disorder
- ZMag.org - 'Eli Lilly, Zyprexa & the Bush Family: The Diseasing of our Malaise' Bruce Levine (May, 2004)